Account
Insider Insights
04.11.2022
UK: NICE conditionally recommends digital cognitiv...

NICE guidance published today on digital health technologies suggest they can be used to help young ...

Read more
Insider Insights
01.11.2022
A winter of discontent? European pharmaceutical so...

EUCOPE and EFPIA have issued a joint statement expressing concerns regarding the implementation of t...

Read more
Insider Insights
27.10.2022
France: Biologists take strike action against PLFS...

The PLFSS requires laboratories to lower the prices of their routine examinations leading to savings...

Read more
Insider Insights
18.10.2022
UK Agencies join with International HTA Partners f...

A cross-border alliance of health technology assessment (HTA) agencies has been announced by the Can...

Read more
Publications
12.10.2022
ISPOR 2022: Do manufacturers still see value in su...

Our research is aimed at identifying trends in terminated appraisals in relation to therapeutic area...

Read more
Publications
12.10.2022
ISPOR 2022: Could Netflix Based Subscription Model...

We analyse subscription-based agreements for antibiotics in Europe to understand how it may address ...

Read more
Publications
12.10.2022
ISPOR 2022: Comparing And Contrasting Early Access...

Identifying EAPs and understanding the opportunities that would best complement manufacturer pricing...

Read more
Insider Insights
12.10.2022
France: Implications for Pharma of the proposed So...

Leem report the changes set out by the Government will heighten the difficulties already being faced...

Read more
Articles
12.10.2022
How important is HTA when launching a biosimilar i...

The short answer to the question “how important is HTA when launching a biosimilar in the EU5?” ...

Read more
Insider Insights
06.10.2022
Germany: Pros and cons of register-based randomise...

Study designs that combine explanatory and pragmatic aspects have recently been weighted up by autho...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.